<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6995028\results\search\disease\results.xml">
  <result pre="engineered antiviral banana lectin inhibits fusion and is efficacious against" exact="influenza" post="virus infection in vivo http://orcid.org/0000-0002-9299-0878Covés-DatsonEvelyn M.ab1KingSteven R.cd1LegendreMaureenc1GuptaAuronic1ChanSusana M.de1GitlinEmilyc1KulkarniVikram V.fPantaleón"/>
  <result pre="engineered banana lectin (carbohydrate-binding protein) has broad-spectrum activity against all" exact="influenza" post="strains tested, including drug-resistant and currently circulating strains; is"/>
  <result pre="administration in mice; and, moreover, is efficacious at treating lethal" exact="influenza" post="infection via clinically pertinent routes of administration. We demonstrate"/>
  <result pre="H84T banana lectin (H84T), to retain broad-spectrum activity against multiple" exact="influenza" post="strains, including pandemic and avian, while largely eliminating the"/>
  <result pre="virus–endosome fusion. These studies reveal that H84T is efficacious against" exact="influenza" post="virus in vivo, and that the loss of mitogenicity"/>
  <result pre="the potential utility of H84T as a broad-spectrum antiinfluenza agent." exact="influenza" post="virus hemagglutinin membrane fusion lectin antiviral Funding DOD |"/>
  <result pre="to 2018 United States season to be only ∼25% against" exact="influenza" post="A subtype H3N2 viruses, which comprised ∼69% of infections"/>
  <result pre="(3), only three classes of drugs are approved to treat" exact="influenza" post="virus infection in the United States: Adamantanes, neuraminidase (NA)"/>
  <result pre="to overwhelmingly high levels of resistance to them among circulating" exact="influenza" post="A strains and due to their intrinsic inactivity against"/>
  <result pre="influenza A strains and due to their intrinsic inactivity against" exact="influenza" post="B strains. The current standard of care treatment is"/>
  <result pre="certain seasons (5, 7). With the twin threats of another" exact="influenza" post="pandemic and emergence of antiviral resistance ever present and"/>
  <result pre="high densities in glycoproteins on the surfaces of viruses. Indeed," exact="influenza" post="viruses are potential targets of lectins because they possess"/>
  <result pre="H84T) (12). H84T is highly efficacious against pandemic, epidemic, and" exact="avian influenza" post="in vitro and against lethal influenza virus infection in"/>
  <result pre="(12). H84T is highly efficacious against pandemic, epidemic, and avian" exact="influenza" post="in vitro and against lethal influenza virus infection in"/>
  <result pre="pandemic, epidemic, and avian influenza in vitro and against lethal" exact="influenza" post="virus infection in vivo when administered intranasally, yet its"/>
  <result pre="Taken together, these studies reveal that H84T is efficacious against" exact="influenza" post="virus in vivo, even when given up to 72"/>
  <result pre="previous work demonstrates that H84T has robust activity against diverse" exact="influenza" post="viruses in vitro, including A/California/04/2009 (H1N1)pdm09, A/California/07/2009 (H1N1)pdm09, A/New"/>
  <result pre="BanLec mutant lacking carbohydrate-binding activity has no antiinfluenza activity. Because" exact="influenza" post="strains resistant to the standard-of-care therapy, oseltamivir, do circulate"/>
  <result pre="H84T shows some, but not striking, synergy with oseltamivir. Since" exact="influenza" post="B infections cannot be distinguished clinically from influenza A"/>
  <result pre="oseltamivir. Since influenza B infections cannot be distinguished clinically from" exact="influenza" post="A infections (23), antiinfluenza agents that have activity against"/>
  <result pre="A infections (23), antiinfluenza agents that have activity against both" exact="influenza" post="A and B are particularly attractive for empiric treatment"/>
  <result pre="We therefore sought to evaluate whether H84T is efficacious against" exact="influenza" post="B virus infection. We found that H84T has EC50"/>
  <result pre="of 0.15 and 0.33 μg/mL (∼4.8 and 11 nM) against" exact="influenza" post="B viruses B/Brisbane/60/2008 (Victoria lineage) and B/Florida/4/2006 (Yamagata lineage),"/>
  <result pre="Appendix, Fig. S4), indicating that H84T is indeed active against" exact="influenza" post="B viruses and has promise as an antiinfluenza A"/>
  <result pre="intranasal administration of H84T protects mice against otherwise lethal H1N1" exact="influenza" post="virus infection (12). To assess whether H84T is also"/>
  <result pre="(12). To assess whether H84T is also efficacious against another" exact="influenza" post="virus strain in vivo, we inoculated C57BL/6J mice via"/>
  <result pre="via aerosol with a lethal dose of A/Hong Kong/8/1968 (H3N2)" exact="influenza" post="virus and treated them with 0.1 mg/kg of H84T"/>
  <result pre="S5). Greater than 80% of H84T-treated mice survived otherwise lethal" exact="influenza" post="virus infection, as compared to &amp;lt;10% of placebo-treated animals,"/>
  <result pre="has robust activity against the two major contemporary subtypes of" exact="influenza" post="A in vivo. H84T, but Not WT BanLec, Is"/>
  <result pre="Well-Tolerated In Vivo. Given that H84T is highly efficacious against" exact="influenza" post="infection in vitro and in vivo via intranasal administration,"/>
  <result pre="of H84T in the lung, a key target organ for" exact="influenza" post="treatment, exceed plasma levels significantly, but in a nonlinear"/>
  <result pre="we inoculated BALB/c mice intranasally with a lethal dose of" exact="influenza" post="and treated them with H84T delivered intraperitoneally once daily"/>
  <result pre="time of prior H84T administration are 100% protected from lethal" exact="influenza" post="infection by H84T treatment (Fig. 2C). These mice also"/>
  <result pre="Fig. 2. Systemic H84T treatment is highly efficacious against lethal" exact="influenza" post="virus infection in mice. (A–C) Therapeutic efficacy of H84T"/>
  <result pre="examined whether subcutaneous administration of H84T conferred protection against lethal" exact="influenza" post="virus infection in mice (Fig. 2D). BALB/c mice were"/>
  <result pre="BALB/c mice were inoculated intranasally with a lethal dose of" exact="influenza" post="virus and survival of the mice monitored after treatment"/>
  <result pre="Virus. A detailed mechanistic understanding of H84T’s ability to inhibit" exact="influenza" post="replication is key to developing it as a potential"/>
  <result pre="types of N-glycans such as can be found on the" exact="influenza" post="virus glycoproteins HA and NA. To ascertain whether H84T"/>
  <result pre="viral proteins. Note that the lower band seen in the" exact="influenza" post="B lanes does not appear to be HA2 as"/>
  <result pre="To understand whether H84T exerts its primary inhibitory effect against" exact="influenza" post="virus replication early or late in the influenza virus"/>
  <result pre="effect against influenza virus replication early or late in the" exact="influenza" post="virus life cycle, we assessed whether viral protein expression"/>
  <result pre="viruses that encompassed the majority of the ∼69% of clinical" exact="influenza" post="infections caused by H3N2 strains in the 2017 to"/>
  <result pre="protein expression (SI Appendix, Fig. S12). Fig. 4. H84T prevents" exact="influenza" post="virus protein expression in MDCK cells. MDCK cells were"/>
  <result pre="at 37 °C. (A and C) Representative immunofluorescent micrographs of" exact="influenza" post="A antigen staining (green) and nuclei (blue) 5 h"/>
  <result pre="(B and D) Quantitation of the number of cells with" exact="influenza" post="protein-positive nuclei per field, as assessed by a trained"/>
  <result pre="sought to further delineate the step at which H84T inhibits" exact="influenza" post="virus replication, hypothesizing that H84T would inhibit influenza virus"/>
  <result pre="H84T inhibits influenza virus replication, hypothesizing that H84T would inhibit" exact="influenza" post="virus at the attachment or fusion steps, since we"/>
  <result pre="may act by inhibiting viral fusion. Fig. 5. H84T inhibits" exact="influenza" post="virus fusion. MDCK cells were pretreated for 1 h"/>
  <result pre="&amp;lt; 0.01, comparing groups indicated by brackets. If fusion of" exact="influenza" post="virus is inhibited by H84T, we reasoned that the"/>
  <result pre="Fig. S14). These results suggest that H84T prevents exit of" exact="influenza" post="viruses from the endosome. Indeed, colocalization between M1 in"/>
  <result pre="of the virus to the endosome. Fig. 6. H84T reduces" exact="influenza" post="virus uncoating. MDCK cells were pretreated for 1 h"/>
  <result pre="group. Error bars represent the SEM. Fig. 7. H84T restricts" exact="influenza" post="virus to the late endosomal/lysosomal compartment. (A) Representative immunofluorescent"/>
  <result pre="internalized into the late endosomal/lysosomal compartment in the absence of" exact="influenza" post="virus infection, we next treated cells with His-tagged H84T"/>
  <result pre="lectin, H84T BanLec, is highly active against an array of" exact="influenza" post="virus strains. While it is somewhat difficult to compare"/>
  <result pre="it is somewhat difficult to compare the overall sensitivity of" exact="influenza" post="viruses to the different lectins without head-to-head comparisons, H84T"/>
  <result pre="(e.g., CV-N EC50 = 0.005 to &amp;gt;10 μg/mL against tested" exact="influenza" post="virus strains). It is notable that H84T is quite"/>
  <result pre="broad-spectrum, capable of inhibiting multiple oseltamivir-resistant as well all other" exact="influenza" post="virus strains tested in this and our previous study"/>
  <result pre="in this and our previous study (12); H84T inhibits both" exact="influenza" post="A and B type viruses and a representative of"/>
  <result pre="proved especially deadly in the 2017 to 2018 Northern Hemisphere" exact="influenza" post="season (2). The finding that there is some synergy"/>
  <result pre="be ideal for all clinical situations (e.g., treating outpatients with" exact="influenza" post="virus infections). Oral administration is not a feasible clinical"/>
  <result pre="to limit activity given that the efficacy of H84T against" exact="influenza" post="infection was not lessened in mice with anti-H84T antibodies."/>
  <result pre="most binding to the H3N2 strain, followed by binding to" exact="influenza" post="B, then the H1N1 strain. Of course, multiple other"/>
  <result pre="the lysosome, accounting for the ability of H84T to decrease" exact="influenza" post="virus replication overall. Our data demonstrate that H84T BanLec"/>
  <result pre="that H84T BanLec has potential as a new antiviral against" exact="influenza" post="viruses. It is very well tolerated and nonmitogenic in"/>
  <result pre="nonmitogenic in vivo and is highly efficacious against otherwise lethal" exact="influenza" post="virus infection via three distinct routes of administration, even"/>
  <result pre="inhibits replication of all oseltamivir-resistant and -sensitive strains and all" exact="influenza" post="A and B strains tested, highlighting its promise as"/>
  <result pre="strains tested, highlighting its promise as an empiric drug for" exact="influenza" post="illness, which will be critically needed in the event"/>
  <result pre="be critically needed in the event of a new pandemic" exact="influenza" post="virus or increasing resistance to neuraminidase inhibitors. H84T is"/>
  <result pre="but also in the sense that it inhibits HIV and" exact="hepatitis" post="C virus as reported previously (12), and Ebola (55),"/>
  <result pre="25 mM Hepes). Supernatant from 293T cells transfected with eight" exact="influenza" post="gene plasmids was used to propagate A/WSN/33 (H1N1) on"/>
  <result pre="to GAPDH expression, qRT-PCR was performed using primers specific to" exact="influenza" post="A M1 and to GAPDH. Primer sequences are provided"/>
  <result pre="and Infectious Diseases for support for testing of H84T against" exact="influenza" post="virus in vitro and in vivo; S. Bedi from"/>
  <result pre="Bedi from the University of Michigan for providing supernatants from" exact="influenza" post="plasmid-transfected cells for virus propagation; S. Hensley from the"/>
  <result pre="T., KelleyN. S., SommerA., BelongiaE. A., Efficacy and effectiveness of" exact="influenza" post="vaccines: A systematic review and meta-analysis. Lancet Infect. Dis.12,"/>
  <result pre="Dis.12, 36–44 (2012).22032844 2FlanneryB.et al., Interim estimates of 2017-18 seasonal" exact="influenza" post="vaccine effectiveness—United States, February 2018. MMWR Morb. Mortal. Wkly."/>
  <result pre="al.; collab: Baloxavir Marboxil Investigators Group, Baloxavir marboxil for uncomplicated" exact="influenza" post="in adults and adolescents. N. Engl. J. Med.379, 913–923"/>
  <result pre="JonesM., DoshiP., Del MarC., Neuraminidase inhibitors for preventing and treating" exact="influenza" post="in healthy adults: Systematic review and meta-analysis. BMJ339, b5106"/>
  <result pre="AvalosR. T., PonimaskinE., NayakD. P., Influenza virus assembly: Effect of" exact="influenza" post="virus glycoproteins on the membrane association of M1 protein."/>
  <result pre="8709–8719 (2000).10954572 10ChlandaP.et al., Structural analysis of the roles of" exact="influenza" post="A virus membrane-associated proteins in assembly and morphology. J."/>
  <result pre="D.et al., Playing hide and seek: How glycosylation of the" exact="influenza" post="virus hemagglutinin can modulate the immune response to infection."/>
  <result pre="1294–1316 (2014).24638204 14MeijerA.et al.; collab: European Influenza Surveillance Scheme, Oseltamivir-resistant" exact="influenza" post="virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis.15,"/>
  <result pre="15DharanN. J.et al.; collab: Oseltamivir-Resistance Working Group, Infections with oseltamivir-resistant" exact="influenza" post="A(H1N1) virus in the United States. JAMA301, 1034–1041 (2009).19255110"/>
  <result pre="F., JulanderJ. G., TarbetE. B., GrossM., NguyenJ., Treatment of oseltamivir-resistant" exact="influenza" post="A (H1N1) virus infections in mice with antiviral agents."/>
  <result pre="13–20 (2012).22809862 17LackenbyA.et al., Emergence of resistance to oseltamivir among" exact="influenza" post="A(H1N1) viruses in Europe. Euro Surveill.13, 8026 (2008).18445375 18SheuT."/>
  <result pre="18SheuT. G.et al., Surveillance for neuraminidase inhibitor resistance among human" exact="influenza" post="A and B viruses circulating worldwide from 2004 to"/>
  <result pre="(2008).18625765 19SimonsenL.et al., The genesis and spread of reassortment human" exact="influenza" post="A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol.24, 1811–1820"/>
  <result pre="ShayD. K., ShuB., CoxN. J., KlimovA. I., Adamantane resistance among" exact="influenza" post="A viruses isolated early during the 2005-2006 influenza season"/>
  <result pre="resistance among influenza A viruses isolated early during the 2005-2006" exact="influenza" post="season in the United States. JAMA295, 891–894 (2006).16456087 21SchinaziR."/>
  <result pre="of combinations of acyclovir with vidarabine or its 5′-monophosphate on" exact="herpes simplex" post="viruses in cell culture and in mice. Antimicrob. Agents"/>
  <result pre="23SuS.et al., Comparing clinical characteristics between hospitalized adults with laboratory-confirmed" exact="influenza" post="A and B virus infection. Clin. Infect. Dis.59, 252–255"/>
  <result pre="RobertsN. A., KlenkH.-D., Neuraminidase is important for the initiation of" exact="influenza" post="virus infection in human airway epithelium. J. Virol.78, 12665–12667"/>
  <result pre="epithelium. J. Virol.78, 12665–12667 (2004).15507653 27SuB.et al., Enhancement of the" exact="influenza" post="A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by"/>
  <result pre="Chem.4, 973–988 (2006).16525538 33KadamR. U., WilsonI. A., Structural basis of" exact="influenza" post="virus fusion inhibition by the antiviral drug Arbidol. Proc."/>
  <result pre="5675–5681 (1984).6098295 36GilbertJ. M., MasonD., WhiteJ. M., Fusion of Rous" exact="sarcoma" post="virus with host cells does not require exposure to"/>
  <result pre="Med. Res. Rev.32, 349–387 (2012).20577974 42SmeeD. F.et al., Treatment of" exact="influenza" post="A (H1N1) virus infections in mice and ferrets with"/>
  <result pre="plasma cells that binds to group 1 and group 2" exact="influenza" post="A hemagglutinins. Science333, 850–856 (2011).21798894 50WeiC.-J.et al., Elicitation of"/>
  <result pre="hemagglutinins. Science333, 850–856 (2011).21798894 50WeiC.-J.et al., Elicitation of broadly neutralizing" exact="influenza" post="antibodies in animals with previous influenza exposure. Sci. Transl."/>
  <result pre="Elicitation of broadly neutralizing influenza antibodies in animals with previous" exact="influenza" post="exposure. Sci. Transl. Med.4, 147ra114 (2012). 51KallewaardN. L.et al.,"/>
  <result pre="al., Structure and function analysis of an antibody recognizing all" exact="influenza" post="A subtypes. Cell166, 596–608 (2016).27453466 52LearJ. D., DeGradoW. F.,"/>
  <result pre="and conformational properties of peptides representing the NH2 terminus of" exact="influenza" post="HA-2. J. Biol. Chem.262, 6500–6505 (1987).3571268 53ShenC.et al., A"/>
  <result pre="multimechanistic antibody targeting the receptor binding site potently cross-protects against" exact="influenza" post="B viruses. Sci. Transl. Med.9, eaam5752 (2017).29046433 54StadlmannJ.et al.,"/>
  <result pre="HobomG., WebsterR. G., A DNA transfection system for generation of" exact="influenza" post="A virus from eight plasmids. Proc. Natl. Acad. Sci."/>
  <result pre="NovikovD., HaydenF. G., GubarevaL. V., Effect of hemagglutinin glycosylation on" exact="influenza" post="virus susceptibility to neuraminidase inhibitors. J. Virol.79, 12416–12424 (2005).16160169"/>
 </snippets>
</snippetsTree>
